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Abstract
Background:  Among patients with hypertension, those with established left ventricular
hypertrophy (LVH) represent a high risk cohort with poor prognosis. We aimed to investigate
differences in characteristics and health care management of such patients treated as inpatients or
outpatients by cardiac specialists.
Methods: Prospective cross-sectional study in patients with hypertension and LVH who were
referred to either inpatient care (rehabilitation hospitals) or to outpatient care (cardiology
practices).
Results: A total of 6358 inpatients (59.6% males; mean age 66.6 years) and 2246 outpatients (59.5%
males; mean age 63.2 years) were followed up for a mean of 23 vs. 52 days, respectively. Inpatients
compared to outpatients had a significantly higher prevalence of coronary heart disease, history of
stroke, renal failure or diabetes. Mean blood pressure of inpatients compared to outpatients was
significantly lower both at entry (150/84 vs. 161/93 mmHg) and at end of follow-up (129/75 vs. 139/
83 mmHg). After adjustment for baseline blood pressure and a propensity score, differences
between out- and inpatients at end of follow-up were 8.0/5.1 mmHg in favour of inpatients. Blood
pressure goals as specified by guidelines were not met by 32% of inpatients and 55% of outpatients.
Conclusion: Inpatients had a higher rate of comorbidities and more advanced atherosclerotic
disease than outpatients. Control of hypertension of inpatients was already better on admission
than in outpatients, and treatment intensity in this group was also higher during the observation
period. While blood pressure lowering was substantial in both groups, there were still a high
proportion of patients who did not achieve treatment goals at discharge.
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Background
Cardiovascular (CV) diseases such as coronary heart dis-
ease, heart failure and stroke are the leading causes of
death in industrialized nations[1,2]. From a public health
perspective, it is imperative to address CV risk factors that
are amenable to treatment such as life-style adjustments
(smoking, obesity), arterial hypertension, lipid disorders,
and diabetes mellitus [3]. In recent years, left ventricular
hypertrophy (LVH) has emerged as further important risk
factor because it indicates target organ damage. Numerous
clinical trials have shown that blood pressure reduction to
predefined target thresholds reduces LVH, and has sub-
stantial influence on subsequent cardiovascular events [4-
6]. Against this background, the need for vigorous antihy-
pertensive therapy in these patients in obvious.
In order to promote evidence-based therapy for hyperten-
sion, a number of guidelines have been issued by national
and international societies, [7-9] and such guidelines are
accepted as standards of care in most countries. Neverthe-
less, physician behaviour is not necessarily strongly influ-
enced by these recommendations [10]. Data from several
countries, including Germany, document that only about
two-thirds of known hypertensive individuals receive any
treatment and less than half of these patients are control-
led to target values [11-13].
These studies addressed the situation in the community or
in the primary care setting. Specialist care might be better
than care from general practitioners [14]. The German
health care system provides inpatient rehabilitation for
patients who have documented target organ damage, par-
ticularly after having experienced a CV event such as acute
coronary syndrome (with or without interventional or
surgical revascularization) or after such an elective inter-
vention without a previous acute event. Usually acute care
hospitals refer patients to rehabilitation centers. The aim
of rehabilitation is to optimize the patients' CV risk profile
and to provide education in terms of life-style interven-
tions [15].
Another option for specialist care is provided in an outpa-
tient setting. Primary care physicians may refer patients
with high CV risk – independent of a previous CV event –
to a cardiac specialist in an outpatient setting for diagnos-
tic and therapeutic support and risk stratification.
To date it has not been investigated whether patients
referred to cardiac specialists in an inpatient versus an out-
patient setting differ from each other in terms of demo-
graphics or comorbidities, are treated differently, or have
different outcomes. Therefore we addressed these ques-
tions in a large-scale prospective study. We focused on
hypertensive patients with comorbid LVH as high risk
group easily identified by cardiac specialists, with high
prevalence and thus substantial public health implica-
tion.
Methods
Study design and patients
This was an observational epidemiological prospective
study (Risk Factors in Hypertension Registry, RIKHY), per-
formed between September 2002 and January 2003 in a
convenience sample of cardiac experts throughout Ger-
many. A total of 251 certified cardiologists (treating out-
patients only) participated, as well as 100 rehabilitation
centers that specialized on the management of patients
with CV diseases (and recruiting inpatients only). They
documented a total of 12 273 patients who met the entry
criteria. Of those, 7 095 (58%) were from inpatient facili-
ties and 5 178 (42%) were from outpatient practices.
Male and female patients were eligible for inclusion in the
present analysis, if they were aged 18 years or older, had a
physician diagnosis of arterial hypertension and concom-
itant LVH, provided informed consent and if their clinical
follow-up duration was scheduled to be at least 3 days.
LVH was assessed according to standard criteria in the
electrocardiogram (using the Lewis, Sokolow-Lyon and/or
Cornell indices), in the echocardiography or both [16-
20]. No formal exclusion criteria were established to doc-
ument as closely as possible the typical patient pattern in
this setting. The study was approved by the certified ethics
committee of the Bavarian Physicians Chamber.
Assessments
Two visits were foreseen, on admission and at discharge,
to document patient data on case report forms. The sched-
ule according to which outpatients were followed up was
not regulated in the study protocol but left to the physi-
cians in order to demonstrate real life patient care. Physi-
cians in both settings recorded demographic data, medical
history, details on cardiovascular risk factors and comor-
bidities, results of physical examination, laboratory and
procedural test results, medications and the dosages of
their patients. Reasons for the initiation of antihyperten-
sive drugs and any changes in medications were noted.
Blood pressure was recorded by trained nurses with a cer-
tified device on admission and at discharge with the
patient sitting for at least 3 minutes. The blood pressure at
the fifth Korotkoff sound was taken as the diastolic pres-
sure. Heart failure was diagnosed with standard clinical
methods detailed elsewhere [21]. The doctor's clinical
assessment of each individual patient by a standardized
questionnaire included indicating the presence or absence
of further predefined concomitant diseases (such as renal
dysfunction, pulmonary disease etc.).BMC Public Health 2006, 6:256 http://www.biomedcentral.com/1471-2458/6/256
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Data management and statistics
Data were stored in a Microsoft Access 97 database and
analyzed with the SAS statistical program (release 8.2),
SPSS (release 13.0) or SYSTAT (release 11.0), respectively.
Descriptive statistics were derived and comparisons
between inpatients and outpatients were conducted by t-
tests or chi square tests as appropriate. Significance was
accepted at the p < 0.05 level. Furthermore, local regres-
sion lines (LOWESS regressions)[22] were computed for a
baseline-adjusted comparison of changes in systolic
blood pressure between groups, corrected for reliability to
avoid the regression-towards-the-mean effect. To cope
with a potential referral bias, a propensity analysis was
performed using a stepwise logistic regression approach
that was based on all available baseline variables [23,24].
Finally, to account for referral effects and hospital- or
practice-related cluster effects, adjusted discharge blood
pressure differences were calculated using a hierarchical
model including the blood pressure at admission and the
propensity score as fixed covariates and facilities as ran-
dom effect.
Results
Demographic data and distribution of risk factors and 
target organ damage
8604 of the recruited patients met the hypertension/LVH
criteria, namely 6358 (74%) inpatients and 2246 (26%)
outpatients. In terms of demographics, there were no
major differences between groups. Inpatients had a mean
age of 66.6 (± 12.1) years, and 59.6% were male; outpa-
tients were 63.2 (± 11.3) years of age; and 59.7% were
male. In both cohorts, mean BMI was 28.2 kg/m2.
Almost all patients (99%) were currently hypertensive and
all had LVH. In 70%, LVH diagnosis was established with
echocardiography, in 8% with electrocardiography, and
in the remainder with both procedures. Additional risk
factors, target organ damage and atherosclerotic manifes-
tations were highly prevalent in both groups, as presented
in Figure 1. The most frequent comorbidity was coronary
artery disease, followed by diabetes mellitus, heart failure
and abnormal renal function. There were significant dif-
ferences in the proportions of comorbidities between the
cohorts: inpatients had significantly higher rates of coro-
nary artery disease, previous stroke or TIA, abnormal renal
function, and diabetes. Conversely, outpatients had
higher rates of carotid stenosis.
Twenty-two baseline characteristics contributed to the
propensity score. Of these, 4 variables accounted for 85%
of the variation in the propensity score: abnormal renal
function, diastolic and systolic blood pressure and family
history for hypertension. After adjustment for the score,
21 out of the 22 baseline variables were not significantly
different between groups, indicating that the propensity
score explained the referral effects rather well.
Duration of follow-up
Inpatients were discharged after a mean of 23 days (3.3
weeks), outpatients were followed up over a mean of 52
days (7.4 weeks), and then referred back to primary care.
Blood Pressure
Mean blood pressure (BP) values on admission was
150.5/84.4 mmHg for inpatients and thus substantially
lower than in outpatients (160.6/92.7 mmHg, difference
between groups p < 0.0001). BP goals at admission
(defined as systolic/diastolic BP < 140/90) were not met
in 72% of inpatients and 92% of outpatients, respectively,
as displayed in Figure 2.
Figure 3 displays a LOWESS regression analysis of the
results of the antihypertensive treatment in inpatients and
outpatients. The regression lines between groups diverge
with increasing SBP admission levels. Thus, at 140
mmHg, the difference was 4.5, at 150 mmHg 6.4, at 160
mmHg 7.3 and at 180 mmHg 11 mmHg in favour of the
inpatients. The slight bow of the red line in inpatients (at
ca. 160 mmHg) marks an assumed threshold of intensi-
fied antihypertensive medication whereas the blue line of
the outpatients remains straight. At the end of follow-up
mean blood pressure was 128.7/75.3 mmHg (difference -
21.8/-9.1 mmHg in inpatients) and 139.2/82.9 mmHg (-
21.4/-9.8 mmHg in outpatients). The proportion of
patients with uncontrolled PB was reduced, yet was still
high in absolute terms in both groups (32% in inpatients
and 55% in outpatients, p < 0.0001; Figure 2). The appar-
ent 10.2/7.6 mmHg difference between inpatients and
outpatients was only slightly reduced to 8.0/5.1 mmHg
after adjustment for baseline and remained highly signifi-
cant (p < 0.0001/p < 0.0001) even after correction for
cluster effects.
Antihypertensive medication
Drug treatment rates increased between the beginning
and end of the survey from 91% to 98% in inpatients and
from 88% to 95% in outpatients. Figure 4 displays the
antihypertensive medication of inpatients and outpa-
tients on admission and at discharge. The mean/median
number of drugs on admission was not significantly dif-
ferent in inpatients (2.0/2) and outpatients (1.9/2). In
both groups, mean number of drugs was increased to 2.6/
3 or 2.5/3, respectively.
On admission, conventional drugs (beta blockers, ACE
inhibitors, calcium channel blockers and diuretics) were
most frequently prescribed. Usage of all drug classes was
increased at discharge, with the exception of ACE inhibi-
tors that were reduced in outpatients. However, this wasBMC Public Health 2006, 6:256 http://www.biomedcentral.com/1471-2458/6/256
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compensated for by a substantial increase in AT1 blockers
in this group. In total, the prescription rates of inhibitors
of the renin-angiotensin system were increased in both
groups at discharge.
Numerous medication changes were made in both indi-
vidual inpatients and outpatients, and in only 25% (inpa-
tients) and 21% (outpatients) medications at entry were
maintained without any changes. Table 1 shows the rea-
sons for medication changes as reported by physicians
and patients. Inadequate response to treatment was the
most frequent reason given. In outpatients this reason was
significantly more frequently stated, as were reasons
related to tolerability and medication compliance. Side
effects were reported in substantial proportions of
patients (7% in inpatients and 21% in outpatients).
Cough was reported in a third of inpatients and two thirds
of outpatients that were intolerant to ACE inhibitors. In
both groups, angioedema were reported (26% and 21% of
those patients who discontinued ACE inhibitors).
Comorbidities and risk factors in inpatients and outpatients on admission Figure 1
Comorbidities and risk factors in inpatients and outpatients on admission. Coronary artery disease includes one or 
more of the following: myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG). 
PAD, peripheral arterial disease.BMC Public Health 2006, 6:256 http://www.biomedcentral.com/1471-2458/6/256
Page 5 of 10
(page number not for citation purposes)
Discussion
The present study was conducted to assess whether high-
risk patients (hypertensive with LVH) treated by cardiac
specialists in the community setting (outpatients) differ
from patients treated by specialists in cardiac rehabilita-
tion centers (inpatients) in terms of patient characteristics
and comorbidities, process of care, and clinical outcomes.
The principle findings of the study are as follows: First,
inpatients had a higher rate of comorbidities and more
advanced atherosclerotic disease. Second, control of
hypertension of inpatients was already better on admis-
sion than in outpatients, and treatment intensity in this
group was also higher during the observation period.
Third, while blood pressure lowering was substantial in
both groups, there were still a high proportion of patients
that did not achieve treatment goals at discharge.
Current guidelines for the management of hypertension
such as the one of the European Hypertension Society/
European Society of Cardiology stress the importance of
searching for comorbidities ("associated clinical condi-
tions" and "target organ damage"), as they substantially
influence prognosis of the patient [8]. These associated
clinical conditions (cerebrovascular disease, heart disease,
renal disease, peripheral vascular disease and advanced
retinopathy) or typical forms of target organ damage
(LVH, arterial wall thickening e.g. in the carotids, or
atherosclerotic plaques, nephropathy or microalbuminu-
ria) have been clearly linked with elevated risk in epidemi-
ological studies. Either of these findings puts the patient
at a risk which is at least as high as in diabetes mellitus, or
matches the combined presence of at least 3 conventional
risk factors (such as higher age, smoking, dyslipidemia,
abdominal obesity, family history of premature cardio-
vascular disease). Depending on the level of blood pres-
sure, such a patient is at least at "high added risk" [8].
The present study focused primarily on LVH as this condi-
tion in cardiac specialist care, when diagnosed, should
trigger intensive blood lowering treatment. This approach
is clearly evidence-based, as a number of studies have doc-
umented substantial, however variably strong, regression
Missed BP goals: Percentages of patients with systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg at discharge Figure 2
Missed BP goals: Percentages of patients with systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg at dis-
charge. DBP, diastolic blood pressure; SBP, systolic blood pressure.BMC Public Health 2006, 6:256 http://www.biomedcentral.com/1471-2458/6/256
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of LVH with various antihypertensive drugs [5]. The large-
scale, long-term LIFE study with losartan is of particular
interest as it showed, in line with Framingham [18] and
HOPE [25] outcomes, that the greater regression of LVH
was paralleled by a reduced incidence of CV events [6].
Mainly based on this study, the ESC/ISH guidelines
explicitly recommend AT1 blockers in patients with LVH
[8].
Our study found that hypertensive patients with LVH
when referred as inpatients were generally sicker than out-
patients when taking into account comorbidities (espe-
cially in view of atherosclerotic complications).
Obviously, referring primary care physicians trust that
these patients will benefit from the characteristics of an
inpatient setting (off-work atmosphere, additional educa-
tional elements, and generally more comprehensive treat-
ment options).
Regarding general hypertension management and medi-
cation choice, cardiac specialists treating inpatients or out-
patients seemed to follow guideline recommendations to
a substantial extent. Antihypertensive treatment during
the observation was intensified, as evidenced by the
increased proportion of medically treated patients, by the
increased number of drugs (2.5 at the discharge), and the
preference of inhibitors of the renin angiotensin system.
The LOWESS regression suggests that inpatients were
somewhat more aggressively treated than outpatients;
however, this was seen only in patients with SBP values
above 160 mmHg. Notably, AT1 receptor blockers were
much more frequently used in outpatients than in inpa-
tients (54% versus 37%), whereas the opposite held true
for ACE inhibitors (66% versus 37%). Potential reasons
for this difference might include cost considerations.
Interestingly outpatients seemed more difficult to man-
age, as they had much higher medication switch rates with
lack of tolerability being three-fold increased compared to
inpatients, and lack of compliance being substantially
increased. It is known from the controlled study setting
[26] as well as in primary care that antihypertensive med-
ication changes due to a variety of reasons are the rule
Change of systolic blood pressure from admission (abscissa) to discharge (ordinate) in inpatients and outpatients Figure 3
Change of systolic blood pressure from admission (abscissa) to discharge (ordinate) in inpatients and outpa-
tients. LOWESS regression. Inpatients are represented by the red regression line, the outpatient values by the blue regression 
line. Values are corrected for reliability (i.e., for regression-to-the-mean effects).
SBP (mmHg) 
on admission 
SBP (mmHg) 
at discharge BMC Public Health 2006, 6:256 http://www.biomedcentral.com/1471-2458/6/256
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rather than the exception [27,28]. All classes seem to have
similar rates of non-response among patients, however,
the newer drugs such as AT1 blockers seem to be associ-
ated under study as well as clinical practice conditions
with better tolerability and consequently, higher persist-
ence rates among treated patients [27,29]. This might be
an explanation why AT1 receptor blockers were preferred
in outpatients. Nonetheless, previous reports from the pri-
mary care setting suggest that there is wide-spread reluc-
tance of physicians to treat hypertension aggressively
enough. Underlying reasons might be, at least in the eld-
erly, the fear of doing harm by applying too-intensive
treatment [30], and as noted in our study, compliance
problems of patients if side effects are experienced [31].
"Clinical inertia", a term that summarizes three related
problems associated with inadequate management of
chronic diseases (overestimation of care provided; use of
'soft' reasons to avoid intensification of therapy; and lack
of education, training and practice organisation aimed at
achieving treatment goals)[32], may also play a major
role, as has recently been suggested as a reason for the sub-
optimal hypertension treatment in the primary care sector
in Germany [33]. Reimbursement issues in Germany at
least in the outpatient setting (fixed budget system [34])
may also contribute to underprescribing and undertreat-
ment.
In terms of treatment outcomes, the mean absolute BP
lowering effect achieved was substantial in both groups
(SBP -22/-21 mmHg, DBP -9/-10 mmHg). In a recent
metaanalysis of 354 randomised controlled trials includ-
ing all current first-line antihypertensives, the mean BP
lowering effect across all drug classes in the standard doses
was SBP/DBP -9.1/-5.5 mmHg [29]. Thus, even when
accounting for the placebo effect which adds to the drug
effect, the BP reduction achieved by cardiac specialists in
our study was not inferior to that achieved under highly
controlled study conditions. Further, they managed pre-
treated patients, with the need to switch or add antihyper-
tensive drugs, and had only a limited follow-up period to
identify an optimized treatment for their patients. The
mean average number of 2.5 drugs in both groups at dis-
Antihypertensive medication on admission and at discharge Figure 4
Antihypertensive medication on admission and at discharge. Figure displays the percentages of antihypertensives by 
class in inpatients and outpatients at admission and discharge. Arrows indicate whether the drugs are more or less frequently 
used at discharge. → denotes more frequently prescribed at discharge compared to admission. ← denotes less frequently pre-
scribed at discharge compared to admission
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charge was still below the average of other observations
and clinical studies to reach BP goals, where up to 5 differ-
ent agents were needed [35]. This is especially the case in
patients with diabetes or nephropathy [36,37], which
made up a substantial fraction of individuals in both
inpatients and outpatients in our study.
The general BP target of <140/90 mmHg were achieved by
inpatients more frequently than by outpatients. This
might be due to the fact that outpatient practitioners had
to manage higher blood pressures at entry. However, even
with comparable baseline values, in the inpatient setting
more pronounced blood pressure reductions were
achieved in the outpatient setting. While control rates as
such in both groups were suboptimal, it has to be stressed
that physicians had to treat "difficult" patients with mul-
tiple comorbidities within the constrictions of a challeng-
ing time frame.
The present study was not designed to answer the ques-
tion whether cardiac specialists in the hospital setting
compared to those in the community setting provide bet-
ter care for patients. A number of studies compared certi-
fied cardiologist care with internists or primary care
physicians, and found improved care for cardiology con-
ditions, mainly in the treatment of patients with acute
myocardial infarction or heart failure [38-43]. However,
differences are multifactorial, and often a function of
study design or patient selection [39]. Treatment initia-
tion in a hospital setting has been reported to be espe-
cially effective for cardioprotective therapies [44]. As
patients referred to rehabilitation centers usually have
been pre-treated in acute care hospitals, they might bene-
fit from better cardiac management. In terms of hyperten-
sion treatment, our study supports this view, because
inpatients seemed to receive more intensive care. Further,
expert physicians credentialed as "hypertension special-
ists" (by the German Hypertension League, similarly to
the American Society of Hypertension Specialists Program
[45]) were not identified nor were we able to analyse their
treatment approaches.
Conclusion
We found that high-risk hypertensive patients with LVH
treated as inpatients versus as outpatients differed in
terms of their profiles, and comorbidities. While their
blood pressure treatment is intensified by cardiac special-
ists in both settings, there is still substantial room for
improvement in blood pressure and corresponding risk
reduction. There was a substantial gap in blood pressure
control rates to published targets. This data confirm the
difficulties reported in achieving treatment goals in other
settings and indications. As the results are more than three
years old, a similar study should be initiated shortly to
assess whether the situation has improved.
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